CN116981449A - 用于引起神经保护的化合物和组合物 - Google Patents

用于引起神经保护的化合物和组合物 Download PDF

Info

Publication number
CN116981449A
CN116981449A CN202180060125.1A CN202180060125A CN116981449A CN 116981449 A CN116981449 A CN 116981449A CN 202180060125 A CN202180060125 A CN 202180060125A CN 116981449 A CN116981449 A CN 116981449A
Authority
CN
China
Prior art keywords
tetramethyl
oxazaphosphine
oxo
compound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180060125.1A
Other languages
English (en)
Chinese (zh)
Inventor
G·鲁宾斯坦
T·莫里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Research Practice College
Rester Medical
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
Original Assignee
Advanced Research Practice College
Rester Medical
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73013493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN116981449(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Advanced Research Practice College, Rester Medical, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Montpellier filed Critical Advanced Research Practice College
Publication of CN116981449A publication Critical patent/CN116981449A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202180060125.1A 2020-05-20 2021-05-20 用于引起神经保护的化合物和组合物 Pending CN116981449A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR2005138A FR3110393B1 (fr) 2020-05-20 2020-05-20 Compose et composition pour induire une neuroprotection
FRFR2005138 2020-05-20
PCT/FR2021/050929 WO2021234324A1 (fr) 2020-05-20 2021-05-20 Compose et composition pour induire une neuroprotection

Publications (1)

Publication Number Publication Date
CN116981449A true CN116981449A (zh) 2023-10-31

Family

ID=73013493

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180060125.1A Pending CN116981449A (zh) 2020-05-20 2021-05-20 用于引起神经保护的化合物和组合物

Country Status (9)

Country Link
US (1) US12611387B2 (https=)
EP (1) EP4142703B8 (https=)
JP (1) JP2023531869A (https=)
KR (1) KR20230013116A (https=)
CN (1) CN116981449A (https=)
CA (1) CA3178633A1 (https=)
ES (1) ES2970378T3 (https=)
FR (1) FR3110393B1 (https=)
WO (1) WO2021234324A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3149773B1 (fr) 2023-06-19 2026-04-17 Rest Therapeutics Nouvelles combinaisons synergiques a base de fenm
WO2026003229A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine pour leur utilisation en tant que medicament
FR3163834A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine
FR3163835A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2584854A1 (en) * 2004-10-15 2006-04-27 Janssen Pharmaceutica N.V. Carbamate compounds for use in treating neurodegenerative disorders
US20120115943A1 (en) * 2008-10-01 2012-05-10 National Taiwan University Composition and method for neuroprotection against excitotoxic injury
US20160107982A1 (en) * 2013-05-29 2016-04-21 M2I Development Novel chemical compounds derived from normemantine and use of same in the medical field
WO2019115833A1 (fr) * 2017-12-15 2019-06-20 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200418446A (en) * 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20090118376A1 (en) * 2007-11-02 2009-05-07 Ru-Band Lu Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
FR3050732B1 (fr) 2016-05-02 2019-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux derives de phosphinolactones et leurs utilisations pharmaceutiques
EP3968977A4 (en) * 2019-05-15 2023-01-11 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS AGAINST STRESS-INDUCED MOOD DISORDERS AND THEIR ASSOCIATED SYMPTOMS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2584854A1 (en) * 2004-10-15 2006-04-27 Janssen Pharmaceutica N.V. Carbamate compounds for use in treating neurodegenerative disorders
US20120115943A1 (en) * 2008-10-01 2012-05-10 National Taiwan University Composition and method for neuroprotection against excitotoxic injury
US20160107982A1 (en) * 2013-05-29 2016-04-21 M2I Development Novel chemical compounds derived from normemantine and use of same in the medical field
WO2019115833A1 (fr) * 2017-12-15 2019-06-20 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete

Also Published As

Publication number Publication date
ES2970378T3 (es) 2024-05-28
FR3110393A1 (fr) 2021-11-26
US20230270695A1 (en) 2023-08-31
US12611387B2 (en) 2026-04-28
KR20230013116A (ko) 2023-01-26
EP4142703B1 (fr) 2023-10-18
JP2023531869A (ja) 2023-07-26
FR3110393B1 (fr) 2022-05-06
EP4142703B8 (fr) 2023-11-22
EP4142703C0 (fr) 2023-10-18
CA3178633A1 (fr) 2021-11-25
WO2021234324A1 (fr) 2021-11-25
EP4142703A1 (fr) 2023-03-08

Similar Documents

Publication Publication Date Title
CN116981449A (zh) 用于引起神经保护的化合物和组合物
US20220117956A1 (en) Lsd for the treatment of alzheimer's disease
JP5615805B2 (ja) 細胞ストレス応答の調節を通したアルツハイマー病および関連障害の処置のための新たな治療アプローチ
Hou et al. Smart Soup, a traditional Chinese medicine formula, ameliorates amyloid pathology and related cognitive deficits
US10912819B2 (en) Neuroprotective peptides derived from activity-dependent neuroprotective protein for treatment of neurological diseases
AU2019445048A1 (en) Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
Liu et al. Bexarotene attenuates focal cerebral ischemia–reperfusion injury via the suppression of JNK/Caspase-3 signaling pathway
CN110214146B (zh) 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物
JP2019123748A (ja) アミロイドβのガランタミンクリアランス
US20220105106A1 (en) Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
JP2017523982A (ja) Ｇｐｃｒ１９作用剤を有効成分として含有する、アルツハイマー病または認知症を予防、治療、または遅延させるための薬学的組成物
US11529319B2 (en) Methods and compositions for treating neurological conditions
JP2024543056A (ja) エダラボンデクスボルネオール含有組成物の認知障害の治療における応用
CN121586584A (zh) Glp-1受体激动剂在治疗神经退行性疾病或病症中的应用
JP7249433B2 (ja) 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物
US20220362180A1 (en) Combined therapy for treating alzheimer's disease
RU2786476C2 (ru) Композиция, содержащая антитело против протофибрилл абета и ингибитор бета-секретазы васе1 для лечения болезни альцгеймера
Davison Investigating the Effects of FTY720 on Spatial Memory and Neuroinflammation in a Rodent Model of Alzheimer’s Disease
Bakar A pharmacovigilance study on Memantine: signal detection of Rhabdomyolysis and death
Villa New therapeutic strategies in neurodegenerative diseases: focus on glaucoma and Alzheimer's disease
WO2025184834A1 (zh) 一种庚酸酯化合物及其用于制备预防和/或治疗神经退行性疾病的药物或功能食品中的用途
Eyjolfsdottir Nerve growth factor in Alzheimer’s disease: biological effects and therapeutic potential
TW201929850A (zh) 醫藥組成物於製備預防或治療不正常乙型-澱粉樣蛋白聚集類疾病之藥物上之用途
de Oliveira Souza The Eye as a Window to the Alzheimer's Disease Brain
MXPA04005450A (es) Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agentes para el tratamiento y prevencion del deterioro cognitivo ligero.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Paris France

Applicant after: Rester medical

Applicant after: UNIVERSITE DE MONTPELLIER

Applicant after: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Applicant after: Advanced Research Practice College

Address before: Montpelier, France

Applicant before: Rester medical

Applicant before: UNIVERSITE DE MONTPELLIER

Applicant before: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Applicant before: Advanced Research Practice College

CB02 Change of applicant information